PDEX PRO DEX INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 788920 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.3%
TTM net income YoY7.5%
TTM EPS YoY9.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR16.7%
Margins
Gross margin32.5%
Operating margin16.8%
Net margin15.1%
FCF margin13.4%
EBITDA margin18.7%
Returns
ROE26.5%
ROA17.1%
ROIC (approx.)27.0%
Asset turnover1.13x
Leverage & solvency
Liabilities / assets35.6%
Debt / equity0.00x
Current ratio4.19x
Interest coverage15.36x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio0.9%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $20.56M | $20.41M | $19.95M | $18.66M | $18.53M | $17.49M | $17.41M | $16.79M |
| Cost of revenue | $13.70M | $13.31M | $13.82M | $12.92M | $13.16M | $14.00M | $11.62M | $11.72M |
| Gross profit | $6.86M | $7.09M | $6.13M | $5.74M | $5.37M | $3.49M | $5.80M | $5.07M |
| R&D expense | $1.21M | $1.02M | $827,000 | $734,000 | $768,000 | $905,000 | $947,000 | $942,000 |
| SG&A expense | $2.13M | $2.54M | $2.21M | $1.75M | $1.49M | $1.24M | $1.21M | $1.44M |
| Operating income | $3.52M | $3.53M | $3.09M | $3.26M | $3.11M | $1.34M | $3.64M | $2.69M |
| Interest expense | $260,000 | $270,000 | $201,000 | $141,000 | $200,000 | $227,000 | $246,000 | $204,000 |
| Pretax income | $3.38M | $3.52M | $5.34M | $2.93M | $6.22M | $1.60M | $4.55M | $2.59M |
| Income tax | $331,000 | $668,000 | $1.40M | $741,000 | $1.54M | $402,000 | $1.28M | $546,000 |
| Net income | $3.05M | $2.86M | $3.94M | $2.19M | $4.68M | $1.20M | $3.27M | $2.04M |
| EBITDA | $3.92M | $3.94M | $3.46M | $3.57M | $3.42M | $1.66M | $3.66M | $3.00M |
| EPS (basic) | 0.95 | — | 1.23 | 0.67 | 1.43 | — | 1.00 | 0.63 |
| EPS (diluted) | 0.92 | — | 1.20 | 0.66 | 1.40 | — | 0.98 | 0.61 |
| Weighted avg. shares (diluted) | 3.32M | — | 3.27M | 3.30M | 3.34M | — | 3.34M | 3.34M |
| Balance sheet | ||||||||
| Cash & equivalents | $11.76M | $8.19M | $6.63M | $5.27M | $514,000 | $419,000 | $4.47M | $66,000 |
| Short-term investments | $1.23M | $1.15M | $986,000 | $864,000 | $10.04M | $6.74M | $5.42M | $4.67M |
| Receivables | $17.51M | $21.20M | $19.47M | $17.88M | $18.23M | $16.43M | $15.86M | $18.47M |
| Inventory | $21.90M | $21.46M | $22.36M | $21.71M | $21.56M | $22.21M | $23.43M | $19.61M |
| Current assets | $53.95M | $53.25M | $53.71M | $49.19M | $50.72M | $47.30M | $49.94M | $44.30M |
| PP&E, net | $5.36M | $5.37M | — | — | — | $5.15M | $6.08M | $6.11M |
| Goodwill | $6.53M | $6.53M | $6.53M | — | — | — | — | — |
| Intangibles | $666,000 | $686,000 | $712,000 | $12,000 | $19,000 | $26,000 | $33,000 | $40,000 |
| Total assets | $76.59M | $74.51M | $74.98M | $62.26M | $64.30M | $61.19M | $64.27M | $60.37M |
| Current liabilities | $12.88M | $12.98M | $14.64M | $12.20M | $13.60M | $14.63M | $18.32M | $17.14M |
| Long-term debt | — | $17.51M | — | — | — | $15.43M | — | — |
| Total debt | — | $17.51M | — | — | — | $15.43M | — | — |
| Total liabilities | $27.24M | $26.88M | $29.78M | $20.62M | $22.79M | $24.56M | $28.99M | $28.55M |
| Shareholders' equity | $49.35M | $47.63M | $45.20M | $41.61M | $41.51M | $36.63M | $35.28M | $31.82M |
| Net debt | — | $9.32M | — | — | — | $15.01M | — | — |
| Shares outstanding | 3.20M | 3.19M | 3.20M | 3.21M | 3.26M | 3.26M | 3.26M | 3.26M |
| Cash flow statement | ||||||||
| Operating cash flow | $6.49M | -$273,000 | $1.63M | $3.57M | $2.31M | -$173,000 | $754,000 | -$4.15M |
| Capital expenditure | $346,000 | $203,000 | $112,000 | $70,000 | $98,000 | $93,000 | $180,000 | $542,000 |
| Free cash flow | $6.14M | -$476,000 | $1.52M | $3.50M | $2.21M | -$266,000 | $574,000 | -$4.69M |
| Investing cash flow | -$346,000 | $198,000 | -$5.05M | $8.87M | -$98,000 | -$992,000 | $1.73M | -$542,000 |
| Financing cash flow | -$2.58M | -$1.73M | $5.46M | -$5.00M | -$2.12M | -$2.89M | $1.93M | $1.68M |
| Depreciation & amortization | $403,000 | $406,000 | $363,000 | $314,000 | $311,000 | $314,000 | $23,000 | $313,000 |
| Stock-based compensation | $135,000 | $177,000 | $186,000 | $164,000 | $161,000 | $154,000 | $158,000 | $130,000 |
| Share buybacks | $600,000 | $600,000 | $601,000 | — | — | $0 | $0 | $1.19M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.